Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors (Q37839783)

24 August 2017

1 reference

title

Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors (English)

1 reference

24 August 2017

1 reference

Jaume Capdevila

1

1 reference

24 August 2017

Ramón Salazar

2

1 reference

24 August 2017

Irene Halperín

3

1 reference

24 August 2017

Albert Abad

4

1 reference

24 August 2017

James C Yao

5

1 reference

24 August 2017

1 March 2011

1 reference

Cancer and Metastasis Reviews

24 August 2017

1 reference

24 August 2017

30 Suppl 1

1 reference

24 August 2017

27-34

1 reference

https://scigraph.springernature.com/pub.10.1007/s10555-011-9290-3

24 August 2017

0 references

cites work

Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

The diagnosis and medical management of advanced neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

PI3K/Akt and apoptosis: size matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Insulinoma in a patient with tuberous sclerosis: is there an association?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Von Hippel-Lindau disease and endocrine tumour susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Multiple endocrine neoplasia type 1 (MEN1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9290-3

10.1007/S10555-011-9290-3

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference